Scientists have discovered a potential alternative to statins that could effectively manage high cholesterol levels. This breakthrough reveals how heightened cholesterol levels disrupt the liver’s natural defenses and introduces a new medication that may counteract this process.
Heart disease, primarily linked to cholesterol, remains a leading global cause of death. Despite the availability of various treatment options like statins, many patients struggle to reach safe cholesterol levels or face challenges with the side effects of current medications.
In the United Kingdom, Atorvastatin (Lipitor) and Simvastatin (Zocor) are commonly prescribed by doctors to control high cholesterol and prevent heart disease. While Atorvastatin is usually the preferred choice for more robust treatment, alternatives such as Fluvastatin, Rosuvastatin, and Pravastatin also exist.
Although statins like Atorvastatin can lead to muscle discomfort in some patients, severe muscle damage is rare, and many individuals experience no adverse effects.
Recent findings by American researchers at the University of California San Diego School of Medicine shed light on a hidden biological mechanism impacted by high cholesterol diets. This mechanism impairs the body’s ability to eliminate harmful low-density lipoprotein (LDL) cholesterol from the bloodstream. The study identified a drug candidate already deemed safe for humans that could potentially address this issue.
Professor Alan Saltiel, the study’s senior author, explained that a high-cholesterol diet reduces the liver’s capacity to clear cholesterol due to a decrease in LDL receptors on liver cells. These receptors play a crucial role in extracting cholesterol from the blood for processing and utilization elsewhere in the body. By uncovering a new pathway linked to cholesterol removal, the researchers have opened up possibilities for novel cholesterol-lowering treatments.
The breakthrough study, published in the journal Nature, combined experiments on mice and human cells to reveal how elevated dietary cholesterol activates a protein called Ral, leading to decreased LDL receptors and elevated blood cholesterol levels. The researchers identified an enzyme called cathepsin A (CTSA) as a central player in this process and successfully lowered LDL cholesterol levels in mice by blocking CTSA with a small molecule inhibitor.
Looking ahead, the study suggests that further research is needed to develop drugs targeting this pathway. However, an existing CTSA inhibitor that underwent early drug development stages for heart failure treatment has shown promise for tackling high cholesterol. Professor Saltiel expressed optimism about moving the investigational drug into a Phase 2 trial focused on high cholesterol, highlighting the potential for a new treatment option to reach patients sooner than anticipated.